Business
GeoVax Announces Issuance of U.S. Patent Covering Enhanced Therapeutic Use of Gedeptin(R) Gene Therapy
Patent Protects Novel Application of Gedeptin Therapy Across Multiple Solid Tumor Types; Supports Expansion of Gedeptin Product Platform ATLANTA, GA - December 9, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology ...
About this update from Geovax Labs, Inc.
[{"type":"image","caption":"","headline":"GeoVax Highlights 2026 as a Pivotal Year for Progress","size":{"original":{"width":140,"height":140,"url":"https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CK3y_RQaAtNDQGf8lPQXOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc","width":140,"height":140}}},{"type":"text","content":"Patent Protects Novel Application of Gedeptin Therapy Across Multiple Solid Tumor Types; Supports Expansion of Gedeptin Product Platform","length":136,"tagName":"p"},{"type":"text","content":"ATLANTA, GA - December 9, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies against cancers and infectious diseases, today announced the issuance of U.S. Patent No. 12,453,760, titled "Enhanced Therapeutic Usage of a Purine Nucleoside Phosphorylase or Nucleoside Hydrolase Prodrug", by the United States Patent and Trademark Office (USPTO). The patent provides composition-of-matter and method-of-use protection for GeoVax's Gedeptin(R) platform in combination with targeted delivery approaches for solid tumors, including head and neck cancer.","length":657,"tagName":"p"},{"type":"text","content":"The newly issued patent, which extends through 2045, enhances the Company's intellectual property estate for Gedeptin and its use across a range of solid tumor cancers - consolidating GeoVax's leadership in the field of targeted gene therapies and supporting ongoing clinical development plans.","length":302,"tagName":"p"},{"type":"text","content":""The issuance of this patent marks an important milestone in the advancement and protection of GeoVax's oncology pipeline," said David A. Dodd, Chairman and Chief Executive Officer of GeoVax. "It underscores our commitment to progressing Gedeptin, both as a monotherapy and in synergistic combination with other oncology treatment approaches as we work to deliver meaningful treatment options for patients with difficult-to-treat solid tumors."","length":468,"tagName":"p"},{"type":"text","content":"The Company is actively preparing for a Phase 2 clinical trial evaluating Gedeptin as a first-line therapy in combination ...